112 related articles for article (PubMed ID: 26732115)
1. Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835).
Tsimafeyeu I; Daeyaert F; Joos JB; Aken KV; Ludes-Meyers J; Byakhov M; Tjulandin S
Med Chem; 2016; 12(4):303-17. PubMed ID: 26732115
[TBL] [Abstract][Full Text] [Related]
2. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
Tsimafeyeu I; Ludes-Meyers J; Stepanova E; Daeyaert F; Khochenkov D; Joose JB; Solomko E; Van Akene K; Peretolchina N; Yin W; Ryabaya O; Byakhov M; Tjulandin S
Eur J Cancer; 2016 Jul; 61():20-8. PubMed ID: 27136102
[TBL] [Abstract][Full Text] [Related]
3. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2.
Khochenkov DA; Solomko ES; Peretolchina NM; Ryabaya OO; Stepanova EV
Bull Exp Biol Med; 2015 Nov; 160(1):84-7. PubMed ID: 26597690
[TBL] [Abstract][Full Text] [Related]
5. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
6. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents.
Poudapally S; Battu S; Velatooru LR; Bethu MS; Janapala VR; Sharma S; Sen S; Pottabathini N; Iska VBR; Katangoor V
Bioorg Med Chem Lett; 2017 May; 27(9):1923-1928. PubMed ID: 28351589
[TBL] [Abstract][Full Text] [Related]
9. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
Cui J; Peng X; Gao D; Dai Y; Ai J; Li Y
Bioorg Med Chem Lett; 2017 Aug; 27(16):3782-3786. PubMed ID: 28687204
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Tsimafeyeu I; Statsenko G; Vladimirova L; Besova N; Artamonova E; Raskin G; Rykov I; Mochalova A; Utyashev I; Gorbacheva S; Kazey V; Gavrilova E; Dragun N; Moiseyenko V; Tjulandin S
Invest New Drugs; 2023 Apr; 41(2):324-332. PubMed ID: 36907947
[TBL] [Abstract][Full Text] [Related]
11. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.
Kachaeva MV; Hodyna DM; Semenyuta IV; Pilyo SG; Prokopenko VM; Kovalishyn VV; Metelytsia LO; Brovarets VS
Comput Biol Chem; 2018 Jun; 74():294-303. PubMed ID: 29698921
[TBL] [Abstract][Full Text] [Related]
13. Sulphonamido-quinoxalines: search for anticancer agent.
Ingle R; Marathe R; Magar D; Patel HM; Surana SJ
Eur J Med Chem; 2013 Jul; 65():168-86. PubMed ID: 23708011
[TBL] [Abstract][Full Text] [Related]
14. Structural Characterization of the Interaction of the Fibroblast Growth Factor Receptor with a Small Molecule Allosteric Inhibitor.
Kappert F; Sreeramulu S; Jonker HRA; Richter C; Rogov VV; Proschak E; Hargittay B; Saxena K; Schwalbe H
Chemistry; 2018 Jun; 24(31):7861-7865. PubMed ID: 29656465
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer.
Grue-Sørensen G; Liang X; Månsson K; Vedsø P; Dahl Sørensen M; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2014 Jan; 24(1):54-60. PubMed ID: 24332494
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.
Wang F; Eric Knabe W; Li L; Jo I; Mani T; Roehm H; Oh K; Li J; Khanna M; Meroueh SO
Bioorg Med Chem; 2012 Aug; 20(15):4760-73. PubMed ID: 22771232
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
[TBL] [Abstract][Full Text] [Related]
18. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
Chen Z; Wang ZC; Yan XQ; Wang PF; Lu XY; Chen LW; Zhu HL; Zhang HW
Bioorg Med Chem Lett; 2015 May; 25(9):1947-51. PubMed ID: 25866240
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2-hydroxyphenyl Moiety: A Series of Novel MMP-2 Inhibitors.
Wang PF; Qiu HY; Baloch SK; Gong HB; Wang ZC; Zhu HL
Chem Biol Drug Des; 2015 Dec; 86(6):1405-10. PubMed ID: 26061284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
